Terns Pharmaceuticals Inc
NASDAQ:TERN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.55
11.23
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TERN stock under the Base Case scenario is 3.121 USD. Compared to the current market price of 6.515 USD, Terns Pharmaceuticals Inc is Overvalued by 52%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Terns Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TERN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Terns Pharmaceuticals Inc
Balance Sheet Decomposition
Terns Pharmaceuticals Inc
Current Assets | 230.2m |
Cash & Short-Term Investments | 225.3m |
Other Current Assets | 4.9m |
Non-Current Assets | 642k |
PP&E | 587k |
Other Non-Current Assets | 55k |
Current Liabilities | 11m |
Accounts Payable | 1.9m |
Accrued Liabilities | 8.8m |
Other Current Liabilities | 320k |
Non-Current Liabilities | 1.2m |
Other Non-Current Liabilities | 1.2m |
Earnings Waterfall
Terns Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-108.2m
USD
|
Operating Income
|
-108.2m
USD
|
Other Expenses
|
12.3m
USD
|
Net Income
|
-95.9m
USD
|
Free Cash Flow Analysis
Terns Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
TERN Profitability Score
Profitability Due Diligence
Terns Pharmaceuticals Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Terns Pharmaceuticals Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
TERN Solvency Score
Solvency Due Diligence
Terns Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Terns Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TERN Price Targets Summary
Terns Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for TERN is 19.295 USD with a low forecast of 5.555 USD and a high forecast of 31.5 USD.
Dividends
Current shareholder yield for TERN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 41 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Its lead program, TERN-101, is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-501 is a thyroid hormone receptor beta (THR-B) agonist with metabolic stability and improved liver distribution. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. Its TERN-601 is its small-molecule Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist program that is intended to be orally administered for NASH and obesity.
Contact
IPO
Employees
Officers
The intrinsic value of one TERN stock under the Base Case scenario is 3.121 USD.
Compared to the current market price of 6.515 USD, Terns Pharmaceuticals Inc is Overvalued by 52%.